Minor bleeding · ambulatory people with cancer without venous thromboembolism receiving systemic therapy
Vitamin K antagonist (VKA) prophylaxis probably leads to higher minor bleeding compared with no prophylaxis (moderate certainty).
1 finding from 1 review
Quality of life ‐ not reported · ambulatory people with cancer without venous thromboembolism receiving systemic therapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Recurrent venous thromboembolism · people > 18 years of age with a diagnosed deep vein thrombosis
Fondaparinux plus vitamin K antagonist showed no clear difference in recurrent venous thromboembolism compared with standard therapy (moderate certainty).
1 finding from 1 review
Major bleeding · people > 18 years of age with a diagnosed deep vein thrombosis
Fondaparinux plus vitamin K antagonist showed no clear difference in major bleeding during the initial treatment compared with standard therapy (moderate certainty).
2 findings from 1 review
All‐cause mortality · people > 18 years of age with a diagnosed deep vein thrombosis
Fondaparinux plus vitamin K antagonist showed no clear difference in all‐cause mortality compared with standard therapy (moderate certainty).
1 finding from 1 review
Heparin‐induced thrombocytopenia ‐ not measured · people > 18 years of age with a diagnosed deep vein thrombosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All harmful effects · people > 18 years of age with a diagnosed deep vein thrombosis
It is very uncertain whether fondaparinux plus vitamin K antagonist changes all harmful effects compared with standard therapy (very low certainty).
1 finding from 1 review
sUA reduction · participants with chronic gout and sUA level > 0.36mmol/L
1 finding from 1 review
Joint pain reduction ‐ not reported · participants with chronic gout and sUA level > 0.36mmol/L
The review found no eligible studies for this question.
1 finding from 1 review
Participant global assessment · participants with chronic gout and sUA level > 0.36mmol/L
The review found no eligible studies for this question.
1 finding from 1 review
Total adverse events · participants with chronic gout and sUA level > 0.36mmol/L
1 finding from 1 review
Tophus regression · participants with chronic gout and sUA level > 0.36mmol/L
The review found no eligible studies for this question.
1 finding from 1 review
Acute gout attacks · participants with chronic gout and sUA level > 0.36mmol/L
The review found no eligible studies for this question.
1 finding from 1 review
Withdrawals due to adverse events · participants with chronic gout and sUA level > 0.36mmol/L
1 finding from 1 review
Incidence: lung cancer · healthy people and healthy male physicians
Vitamin A showed no clear difference in incidence: lung cancer compared with placebo (high certainty).
1 finding from 1 review
Incidence: lung cancer ‐ women · healthy male physicians, period: 1997 to 2007 and female health professionals, period: 1998 to 2005
Vitamin C leads to higher incidence: lung cancer ‐ women compared with placebo (high certainty).
1 finding from 1 review
Mortality: lung cancer ‐ men · healthy male physicians, period: 1997 to 2007 and female health professionals, period: 1998 to 2005
Vitamin C showed no clear difference in mortality: lung cancer ‐ men compared with placebo (high certainty).
1 finding from 1 review
Adverse events · healthy male physicians, period: 1997 to 2007 and female health professionals, period: 1998 to 2005
1 finding from 1 review
no estimate extracted
1 study · 1 participants
High
Incidence: all cancers · healthy male physicians, period: 1997 to 2007 and female health professionals, period: 1998 to 2005
Vitamin C showed no clear difference in incidence: all cancers compared with placebo (high certainty).
1 finding from 1 review
Mortality: all cancers · healthy male physicians, period: 1997 to 2007 and female health professionals, period: 1998 to 2005
Vitamin C showed no clear difference in mortality: all cancers compared with placebo (high certainty).
1 finding from 1 review